Human Trials

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Roche announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Herceptin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC).

Fully-human BCMA CAR-T clinical results to treat relapsed/refractory multiple myeloma co-developed by IASO BIO and Innovent presented at 2019 ASH Annual Meeting

IASO Biotherapeutics, a clinical-stage biotechnology company advancing the development of innovative therapies for cancer, had the latest clinical data presented on their potential best-in-class therapy at the “Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma” session during the prestigious 61st Annual American Society of Hematology (ASH) Meeting & Exposition, December 7-10 in Orlando.

Trastuzumab deruxtecan achieves tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.

Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials

Danish medical dermatology firm Leo Pharma announced that its tralokinumab has achieved all primary and secondary endpoints in three phase 3 studies for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Vedanta Biosciences announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in patients with select types of advanced or metastatic cancer.

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Novartis announced results from two analyses of real-world experience with Kymriah (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications.

Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma

Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma.

Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL

AstraZeneca presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, a standard chemo-immunotherapy treatment, in patients with previously untreated chronic lymphocytic leukaemia (CLL).

Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial

Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.